Does personalized medicine cut the mustard when it comes to treating cancer? Richard Smith, a former editor of the British Medical Journal, believes that it does not. Using the mustard metaphor, he shows how personalized medicine undermines the pharmaceutical industry’s profits. If the one-size-fits-all approach to prescribing cancer drugs were abandoned, drug companies would be forced to change their business model, most notably by increasing prices radically – or stop producing the drugs altogether.
View the original article here: Personalized Medicine’s Perverse Economics
Personalized medicine’s perverse economics
Donna Dickenson | Project Syndicate | December 21, 2012
{{ reviewsTotal }}{{ options.labels.singularReviewCountLabel }}
{{ reviewsTotal }}{{ options.labels.pluralReviewCountLabel }}
{{ options.labels.newReviewButton }}
{{ userData.canReview.message }}
Infographics | More... |
Are pesticide residues on food something to worry about?
In 1962, Rachel Carson’s Silent Spring drew attention to pesticides and their possible dangers to humans, birds, mammals and the ...
Most Popular
- Is tilapia a human-made freak that we should avoid — or an evolutionary rockstar?
- 30 years later in Romania: What happened to the babies deprived of human contact?
- Evolution’s ‘great leap forward’: When did humans cross the intelligence rubicon?
- Why is it so difficult to find a treatment for Huntington’s Disease?
- Embryos aren’t female by ‘default’ after all, study shows
- Viewpoint: Agribashing and the French media — Paper withdraws ‘fake news’ viral article claiming drinking water contains 200 ‘dangerous’ chemicals
- How common is incest? Rise of genetic testing reveals disturbing evidence
- Gene-edited chickens could reduce the threat of bird flu spread and promote sustainability
- Viewpoint: Iowa farmer explains support for state bill to restrict suits against manufacturers of glyphosate and other pesticides that follow federal guidelines
- How Freddie Mercury got his voice: It wasn’t his teeth